Peptides Similar to Taspoglutide
Compare Taspoglutide with related peptides and alternatives
📌TL;DR
- •3 similar peptides identified
- •Semaglutide: High - Both are once-weekly GLP-1 receptor agonists based on modified GLP-1 sequences for type 2 diabetes
- •Albiglutide: High - Both were once-weekly GLP-1 agonists that ultimately failed commercially or in development
Comparison chart of Taspoglutide and similar peptides
Infographic pending generation
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| Taspoglutide (current) | - | - |
| Semaglutide | High - Both are once-weekly GLP-1 receptor agonists based on modified GLP-1 sequences for type 2 diabetes | Semaglutide uses C18 fatty diacid acylation for albumin binding (no depot), while taspoglutide used a zinc-depot formulation. Semaglutide has far lower immunogenicity (<1% vs 49%) and better GI tolerability. |
| Albiglutide | High - Both were once-weekly GLP-1 agonists that ultimately failed commercially or in development | Albiglutide achieved approval (Tanzeum) but was withdrawn for commercial failure. It used albumin fusion rather than zinc-depot formulation. Albiglutide had lower GI side effects but also lower efficacy. |
| Liraglutide | High - Both are GLP-1 receptor agonists for type 2 diabetes, though liraglutide is once-daily while taspoglutide was once-weekly | Liraglutide uses C16 fatty acid acylation for albumin binding with once-daily dosing. It is FDA-approved and well established. Taspoglutide had superior HbA1c efficacy but far worse tolerability. |
SemaglutideHigh - Both are once-weekly GLP-1 receptor agonists based on modified GLP-1 sequences for type 2 diabetes
Differences
Semaglutide uses C18 fatty diacid acylation for albumin binding (no depot), while taspoglutide used a zinc-depot formulation. Semaglutide has far lower immunogenicity (<1% vs 49%) and better GI tolerability.
Advantages
FDA-approved with three indications, proven cardiovascular benefit (SELECT trial), oral formulation available, dramatically better tolerability and safety profile
Disadvantages
None relative to taspoglutide; semaglutide is superior in all clinically relevant parameters
AlbiglutideHigh - Both were once-weekly GLP-1 agonists that ultimately failed commercially or in development
Differences
Albiglutide achieved approval (Tanzeum) but was withdrawn for commercial failure. It used albumin fusion rather than zinc-depot formulation. Albiglutide had lower GI side effects but also lower efficacy.
Advantages
Albiglutide reached approval and demonstrated CV benefit in HARMONY Outcomes; better tolerability than taspoglutide
Disadvantages
Withdrew from market due to low sales; lower efficacy than other GLP-1 agonists for HbA1c and weight; complex reconstitution process
LiraglutideHigh - Both are GLP-1 receptor agonists for type 2 diabetes, though liraglutide is once-daily while taspoglutide was once-weekly
Differences
Liraglutide uses C16 fatty acid acylation for albumin binding with once-daily dosing. It is FDA-approved and well established. Taspoglutide had superior HbA1c efficacy but far worse tolerability.
Advantages
FDA-approved with proven safety record, CV benefit (LEADER trial), pediatric obesity indication, well-characterized over a decade of use
Disadvantages
Requires daily injection, lower weight loss efficacy than semaglutide, gradually being superseded by weekly GLP-1 agonists
Peptides Related to Taspoglutide#
Taspoglutide belongs to the GLP-1 receptor agonist class, a highly competitive therapeutic area in which it failed to achieve regulatory approval. The comparison below illustrates why taspoglutide was discontinued while structurally similar but pharmacologically superior agents succeeded.
Semaglutide (Ozempic / Wegovy / Rybelsus)#
Semaglutide is the most successful GLP-1 receptor agonist, with three FDA-approved formulations and the most extensive clinical evidence base including the landmark SELECT cardiovascular outcomes trial.
Why semaglutide succeeded where taspoglutide failed: Both aimed for once-weekly GLP-1 agonism, but their molecular strategies differed fundamentally. Semaglutide uses a C18 fatty diacid conjugation at Lys26 for albumin binding, creating a circulating reservoir with a true ~7-day half-life. Taspoglutide relied on a zinc-depot formulation at the injection site. The albumin-binding approach produced a cleaner pharmacokinetic profile with much lower immunogenicity (<1% vs 49%) and better GI tolerability.
Albiglutide (Tanzeum / Eperzan)#
Albiglutide was another once-weekly GLP-1 agonist that reached FDA approval in 2014 but was withdrawn from the market in 2017 due to commercial failure. It used albumin fusion to achieve a ~5-day half-life.
Comparison: Both taspoglutide and albiglutide ultimately failed, but for different reasons. Taspoglutide was too toxic (GI and immunogenicity), while albiglutide was too ineffective (lower HbA1c reduction and weight loss than competitors). Albiglutide did demonstrate cardiovascular benefit in the HARMONY Outcomes trial, published after market withdrawal.
Liraglutide (Victoza / Saxenda)#
Liraglutide, another Novo Nordisk GLP-1 agonist, uses C16 fatty acid acylation for once-daily dosing. While requiring more frequent injection than taspoglutide, liraglutide succeeded because of manageable GI side effects and a clean safety profile.
Summary Comparison#
| Feature | Taspoglutide | Semaglutide | Albiglutide | Liraglutide |
|---|---|---|---|---|
| Dosing | Weekly SC | Weekly SC / Daily oral | Weekly SC | Daily SC |
| HbA1c reduction | -1.24 to -1.31% | -1.5 to -2.2% | -0.6 to -0.8% | -1.1 to -1.2% |
| Nausea rate | 53-59% | 15-44% | 10-12% | 20-39% |
| Antibody formation | 49% | <1% | <5% | <1% |
| CV outcomes | Not tested | Positive | Positive | Positive |
| Regulatory status | Terminated | Approved | Approved then withdrawn | Approved |
Comparison Context#
Taspoglutide belongs to the Metabolic category of research peptides. Comparing Taspoglutide with related compounds helps researchers understand its relative positioning in the therapeutic landscape. Each compound has distinct advantages and limitations that should be considered based on the specific research question or clinical need.
Detailed Comparisons#
The following peptides and compounds are most closely related to Taspoglutide in mechanism, indication, or therapeutic category:
Taspoglutide vs Semaglutide#
Similarity: High - Both are once-weekly GLP-1 receptor agonists based on modified GLP-1 sequences for type 2 diabetes
Key Differences: Semaglutide uses C18 fatty diacid acylation for albumin binding (no depot), while taspoglutide used a zinc-depot formulation. Semaglutide has far lower immunogenicity (<1% vs 49%) and better GI tolerability.
Advantages of Semaglutide: FDA-approved with three indications, proven cardiovascular benefit (SELECT trial), oral formulation available, dramatically better tolerability and safety profile
Disadvantages of Semaglutide: None relative to taspoglutide; semaglutide is superior in all clinically relevant parameters
Researchers choosing between Taspoglutide and Semaglutide should consider the development stage, available evidence, and specific research objectives when making their selection.
Taspoglutide vs Albiglutide#
Similarity: High - Both were once-weekly GLP-1 agonists that ultimately failed commercially or in development
Key Differences: Albiglutide achieved approval (Tanzeum) but was withdrawn for commercial failure. It used albumin fusion rather than zinc-depot formulation. Albiglutide had lower GI side effects but also lower efficacy.
Advantages of Albiglutide: Albiglutide reached approval and demonstrated CV benefit in HARMONY Outcomes; better tolerability than taspoglutide
Disadvantages of Albiglutide: Withdrew from market due to low sales; lower efficacy than other GLP-1 agonists for HbA1c and weight; complex reconstitution process
Researchers choosing between Taspoglutide and Albiglutide should consider the development stage, available evidence, and specific research objectives when making their selection.
Taspoglutide vs Liraglutide#
Similarity: High - Both are GLP-1 receptor agonists for type 2 diabetes, though liraglutide is once-daily while taspoglutide was once-weekly
Key Differences: Liraglutide uses C16 fatty acid acylation for albumin binding with once-daily dosing. It is FDA-approved and well established. Taspoglutide had superior HbA1c efficacy but far worse tolerability.
Advantages of Liraglutide: FDA-approved with proven safety record, CV benefit (LEADER trial), pediatric obesity indication, well-characterized over a decade of use
Disadvantages of Liraglutide: Requires daily injection, lower weight loss efficacy than semaglutide, gradually being superseded by weekly GLP-1 agonists
Researchers choosing between Taspoglutide and Liraglutide should consider the development stage, available evidence, and specific research objectives when making their selection.
Related Reading#
Frequently Asked Questions About Taspoglutide
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer